Market Closed -
Euronext Bruxelles
09:54:35 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
0.0001
EUR
|
0.00%
|
|
0.00%
|
-88.89%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
138.5
|
113
|
97.84
|
70.95
|
7.81
|
2.923
|
Enterprise Value (EV)
1 |
53.42
|
62.26
|
74.13
|
73.06
|
12.24
|
13.58
|
P/E ratio
|
-3.58
x
|
-2.18
x
|
-3.49
x
|
-2.39
x
|
-0.05
x
|
-0.08
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
26
x
|
28.6
x
|
47.1
x
|
62.9
x
|
13.1
x
|
11.1
x
|
EV / Revenue
|
10
x
|
15.8
x
|
35.7
x
|
64.8
x
|
20.6
x
|
51.6
x
|
EV / EBITDA
|
-1.45
x
|
-1.77
x
|
-2.62
x
|
-2.68
x
|
-0.56
x
|
-1.14
x
|
EV / FCF
|
-3.46
x
|
-3.48
x
|
-4.58
x
|
-4.37
x
|
-0.99
x
|
-2.03
x
|
FCF Yield
|
-28.9%
|
-28.7%
|
-21.9%
|
-22.9%
|
-101%
|
-49.2%
|
Price to Book
|
1.32
x
|
2.12
x
|
3.89
x
|
-65.8
x
|
-1.7
x
|
-0.24
x
|
Nbr of stocks (in thousands)
|
38,272
|
38,292
|
38,292
|
39,067
|
411,072
|
3,247,913
|
Reference price
2 |
3.620
|
2.950
|
2.555
|
1.816
|
0.0190
|
0.000900
|
Announcement Date
|
4/4/19
|
4/3/20
|
4/2/21
|
3/26/22
|
3/27/23
|
4/12/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5.32
|
3.946
|
2.078
|
1.128
|
0.595
|
0.263
|
EBITDA
1 |
-36.91
|
-35.13
|
-28.3
|
-27.29
|
-21.88
|
-11.94
|
EBIT
1 |
-39.24
|
-36.39
|
-28.5
|
-27.37
|
-21.95
|
-11.98
|
Operating Margin
|
-737.61%
|
-922.15%
|
-1,371.27%
|
-2,426.24%
|
-3,688.4%
|
-4,555.89%
|
Earnings before Tax (EBT)
1 |
-38.77
|
-52.09
|
-28.56
|
-29.59
|
-31.69
|
-18.97
|
Net income
1 |
-38.47
|
-51.83
|
-28.01
|
-29.16
|
-31.68
|
-18.97
|
Net margin
|
-723.2%
|
-1,313.41%
|
-1,348.03%
|
-2,584.93%
|
-5,325.21%
|
-7,212.55%
|
EPS
2 |
-1.010
|
-1.353
|
-0.7315
|
-0.7591
|
-0.3727
|
-0.0115
|
Free Cash Flow
1 |
-15.44
|
-17.86
|
-16.2
|
-16.72
|
-12.32
|
-6.686
|
FCF margin
|
-290.26%
|
-452.73%
|
-779.59%
|
-1,482.15%
|
-2,069.81%
|
-2,542.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/4/19
|
4/3/20
|
4/2/21
|
3/26/22
|
3/27/23
|
4/12/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
2.11
|
4.43
|
10.7
|
Net Cash position
1 |
85.1
|
50.7
|
23.7
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.0774
x
|
-0.2022
x
|
-0.8926
x
|
Free Cash Flow
1 |
-15.4
|
-17.9
|
-16.2
|
-16.7
|
-12.3
|
-6.69
|
ROE (net income / shareholders' equity)
|
-32.5%
|
-65.7%
|
-72.9%
|
-247%
|
1,114%
|
214%
|
ROA (Net income/ Total Assets)
|
-18.5%
|
-25.3%
|
-35.9%
|
-64.4%
|
-88.9%
|
-80.8%
|
Assets
1 |
208.1
|
205
|
78.1
|
45.31
|
35.65
|
23.48
|
Book Value Per Share
2 |
2.740
|
1.390
|
0.6600
|
-0.0300
|
-0.0100
|
-0
|
Cash Flow per Share
2 |
1.690
|
1.110
|
0.6400
|
0.2500
|
0.0100
|
0
|
Capex
1 |
0.2
|
0.13
|
0.12
|
0.03
|
0.06
|
0
|
Capex / Sales
|
3.67%
|
3.37%
|
5.73%
|
2.84%
|
9.92%
|
0.38%
|
Announcement Date
|
4/4/19
|
4/3/20
|
4/2/21
|
3/26/22
|
3/27/23
|
4/12/24
|
|
1st Jan change
|
Capi.
|
---|
| -88.89% | 614K | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|